Literature DB >> 30465091

Re-fracture and correlated risk factors in patients with osteoporotic vertebral fractures.

Xinling Ma1, Haiou Xia2, Jinhua Wang3,4, Xiaoxiao Zhu1, Fangyan Huang3, Liuxue Lu5, Lanyan He5.   

Abstract

Re-fracture risk is higher following osteoporotic fracture. However, there is no accurately reported rate of re-fracture incidence in southwest China. The purpose of this study was to describe the osteoporotic vertebral fracture (OVF) survival for re-fracture state and analyze the risk of re-fracture. This historical cohort study was conducted in four hospitals in southwest China. Patients aged ≥ 50 years (n = 586) with OVF who were supposed to receive anti-osteoporosis drugs after the fracture were included (2012-2017). Telephone follow-up and referring case files were used to estimate the survival for re-fracture and identify the determinants of re-fracture. A total of 555 patients completed the follow-up investigation. Overall, 285 patients experienced a re-fracture, and the longest follow-up investigation time was 72 months. The survival rates for re-fracture at 12 months, 24 months, 36 months, and 48 months were 82.0%, 71.5%, 61.7%, and 34.0%, respectively. The factors correlated with re-fracture hazard were advanced age [hazard ratio (HR) = 1.996], being female (HR = 1.342), smoking (HR = 1.435), history of hypertension (HR = 1.219) and diabetes (HR = 3.271), and persistence of taking anti-osteoporosis drugs after fracture [0-3 months, 4-6 months, 7-12 months, and more than 12 months (HR = 0.703)]. OVF patients with advanced age, who were female, smoked, had fracture with hypertension or diabetes, and who complied poorly with anti-osteoporosis drug treatment presented higher prevalence of re-fracture and low anti-osteoporosis adherence in southwest China. The management of anti-osteoporosis after fracture is necessary in this area.

Entities:  

Keywords:  Anti-osteoporosis; Osteoporosis; Osteoporotic vertebral fracture; Re-fracture

Mesh:

Year:  2018        PMID: 30465091     DOI: 10.1007/s00774-018-0974-4

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  21 in total

1.  Risk of subsequent fracture after low-trauma fracture in men and women.

Authors:  Jacqueline R Center; Dana Bliuc; Tuan V Nguyen; John A Eisman
Journal:  JAMA       Date:  2007-01-24       Impact factor: 56.272

2.  Predictors of re-fracture amongst patients managed within a secondary fracture prevention program: a 7-year prospective study.

Authors:  K Ganda; A Schaffer; M J Seibel
Journal:  Osteoporos Int       Date:  2014-09-05       Impact factor: 4.507

3.  Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians.

Authors:  Amir Qaseem; Mary Ann Forciea; Robert M McLean; Thomas D Denberg; Michael J Barry; Molly Cooke; Nick Fitterman; Russell P Harris; Linda L Humphrey; Devan Kansagara; Robert M McLean; Tanveer P Mir; Holger J Schünemann
Journal:  Ann Intern Med       Date:  2017-05-09       Impact factor: 25.391

4.  Assessment of compliance with osteoporosis treatment and its consequences in a managed care population.

Authors:  Krista F Huybrechts; Khajak J Ishak; J Jaime Caro
Journal:  Bone       Date:  2005-12-05       Impact factor: 4.398

5.  Targeted intervention reduces refracture rates in patients with incident non-vertebral osteoporotic fractures: a 4-year prospective controlled study.

Authors:  A Lih; H Nandapalan; M Kim; C Yap; P Lee; K Ganda; M J Seibel
Journal:  Osteoporos Int       Date:  2010-11-24       Impact factor: 4.507

6.  Risk of new vertebral fracture in the year following a fracture.

Authors:  R Lindsay; S L Silverman; C Cooper; D A Hanley; I Barton; S B Broy; A Licata; L Benhamou; P Geusens; K Flowers; H Stracke; E Seeman
Journal:  JAMA       Date:  2001-01-17       Impact factor: 56.272

7.  Burden of high fracture probability worldwide: secular increases 2010-2040.

Authors:  A Odén; E V McCloskey; J A Kanis; N C Harvey; H Johansson
Journal:  Osteoporos Int       Date:  2015-05-28       Impact factor: 4.507

8.  Clinical subsequent fractures cluster in time after first fractures.

Authors:  T A C M van Geel; S van Helden; P P Geusens; B Winkens; G-J Dinant
Journal:  Ann Rheum Dis       Date:  2008-08-03       Impact factor: 19.103

9.  Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases.

Authors:  Marsha A Raebel; Julie Schmittdiel; Andrew J Karter; Jennifer L Konieczny; John F Steiner
Journal:  Med Care       Date:  2013-08       Impact factor: 2.983

10.  The risk of major and any (non-hip) fragility fracture after hip fracture in the United Kingdom: 2000-2010.

Authors:  D Gibson-Smith; C Klop; P J M Elders; P M J Welsing; N van Schoor; H G M Leufkens; N C Harvey; T P van Staa; F de Vries
Journal:  Osteoporos Int       Date:  2014-07-08       Impact factor: 4.507

View more
  10 in total

1.  Association between handgrip strength and subsequent vertebral-fracture risk following percutaneous vertebral augmentation.

Authors:  Shu-Bao Zhang; Hao Chen; Hao-Wei Xu; Shan-Jin Wang; Yu-Yang Yi; De-Sheng Wu
Journal:  J Bone Miner Metab       Date:  2020-07-20       Impact factor: 2.626

2.  Risk factors for subsequent vertebral fractures following a previous hip fracture.

Authors:  Sang-Min Park; Sung Jun Go; Heesoo Han; Jung Wee Park; Young-Kyun Lee; Ho-Joong Kim; Jin S Yeom; Kyung-Hoi Koo
Journal:  J Bone Miner Metab       Date:  2020-07-18       Impact factor: 2.626

3.  Strontium ranelate incorporated 3D porous sulfonated PEEK simulating MC3T3-E1 cell differentiation.

Authors:  Yingxiao Sun; Xingdan Liu; Ji Tan; Dan Lv; Wengang Song; Rui Su; Ling Li; Xuanyong Liu; Liping Ouyang; Yun Liao
Journal:  Regen Biomater       Date:  2020-11-28

4.  Incidence of different types of subsequent fractures and related mortality in Taiwan.

Authors:  Jiun-Liang Chen; Ta-Wei Tai; Che-Yi Chou; Chieh-Ko Ku; Li-Nien Chien; Tsan-Wen Huang; Chao-Hsuin Tang
Journal:  Arch Osteoporos       Date:  2022-04-01       Impact factor: 2.617

5.  Correlation of Sagittal Imbalance and Recollapse after Percutaneous Vertebroplasty for Thoracolumbar Osteoporotic Vertebral Compression Fracture: A Multivariate Study of Risk Factors.

Authors:  Whoan Jeang Kim; Sang Beom Ma; Hyun Min Shin; Dae Geon Song; Jae Won Lee; Shan Haw Chang; Kun Young Park; Won Sik Choy; Tae Ho Oh
Journal:  Asian Spine J       Date:  2021-08-20

6.  The effect of bone cement distribution on clinical efficacy after percutaneous kyphoplasty for osteoporotic vertebral compression fractures.

Authors:  Shuangjun He; Yijian Zhang; Nanning Lv; Shujin Wang; Yaowei Wang; Shuhua Wu; Fan He; Angela Chen; Zhonglai Qian; Jianhong Chen
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

Review 7.  Fracture, nonunion and postoperative infection risk in the smoking orthopaedic patient: a systematic review and meta-analysis.

Authors:  Maria Anna Smolle; Lukas Leitner; Nikolaus Böhler; Franz-Josef Seibert; Mathias Glehr; Andreas Leithner
Journal:  EFORT Open Rev       Date:  2021-11-19

8.  Association Between Osteoporosis and Refracture Rate Among Patients With Hip Fractures at King Abdulaziz Medical City, Saudi Arabia.

Authors:  Ali H AlYami; Majed N Alosaimi; Mohammed S Alshehri; Abdulhamid T Alghamdi; Majd A SaemAldahar; Turki A Alsafrani; Albaraa A Dabroom; Ibrahim A Kattan; Fares M Sindi; Azzam M Azaya; Bandar N AlMaeen
Journal:  Cureus       Date:  2022-02-13

9.  Study on the influence of balloon dilation mode on the intravertebral cleft of osteoporotic fracture.

Authors:  Nanning Lv; Xiaoxiao Feng; Haojun Liu; Xuejun Jia; Shanqin Han; Mingming Liu
Journal:  BMC Surg       Date:  2022-09-30       Impact factor: 2.030

10.  Study on the Relationship between the Use of Bisphosphonates for Antiosteoporosis and Vertebral Re-Fracture after Vertebroplasty.

Authors:  Li Qian; Qian Chen; Dashou Wang; Qi Pan; Qianhong Jian; Yinghong Ma
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-23       Impact factor: 2.650

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.